EcoR1 Capital, LLC — SEC insider filings
SEC reporting owner CIK 1587114. 59 insider filings on record with FilingPulse; latest filed 2026-11-18.
Transaction summary — filings shown
Covers the 50 most recent of 59 filings on record, filed 2021-03-25 to 2026-11-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 87 legs across 38 filings — 34,704,574 shares, $332,369,779 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 23 legs across 10 filings — 91,466,922 shares, $220,476,289 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 20.
- Largest priced transaction: sale of 4,705,575 shares @ $13.81 ($64,999,990) in First Tracks Biotherapeutics, Inc., filed 2026-04-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | 10% owner | 5 | 3 legs · 2,237,736 sh · $60,247,149 | 4 legs · 7,342,420 sh · $81,680,406 | 2 |
| Zymeworks Inc. (ZYME) | Director, 10% owner | 22 | 45 legs · 10,315,335 sh · $107,392,396 | — | 5 |
| ANAPTYSBIO, INC (ANAB) | Director, 10% owner | 6 | 14 legs · 1,770,687 sh · $51,405,856 | 1 leg · 668,237 sh · $14,453,966 | — |
| First Tracks Biotherapeutics, Inc. (TRAX) | 10% owner | 1 | — | 1 leg · 4,705,575 sh · $64,999,990 | — |
| Aktis Oncology, Inc. (AKTS) | Director | 1 | 2 legs · 2,222,222 sh · $39,999,996 | — | 10 |
| iTeos Therapeutics, Inc. (ITOS) | 10% owner | 1 | 2 legs · 4,958,978 sh · $38,685,562 | — | — |
| Corvus Pharmaceuticals, Inc. (CRVS) | 10% owner | 1 | — | 2 legs · 5,000,000 sh · $25,059,900 | — |
| Nuvation Bio Inc. (NUVB) | Director | 4 | 16 legs · 11,483,868 sh · $21,473,857 | 2 legs · 208,142 sh · $2,072,642 | — |
| Odonate Therapeutics, Inc. (ODT) | 10% owner | 1 | 1 leg · 185,941 sh · $308,662 | 4 legs · 5,887,610 sh · $9,741,063 | — |
| Voyager Therapeutics, Inc. (VYGR) | 10% owner | 2 | 2 legs · 477,400 sh · $2,662,047 | 3 legs · 902,400 sh · $7,142,343 | — |
+5 more issuers among the filings shown — every filing appears in the table below.
Insider filings — EcoR1 Capital, LLC
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | ANAPTYSBIO, INC (ANAB) jointly with NODELMAN OLEG | Purchase (P): 84,120 @ $45.66 · Purchase (P): 152,367 @ $45.66 · Purchase (P): 138,093 @ $46.54 | EDGAR |
| 2026-05-11 | 4 | Atara Biotherapeutics, Inc. (ATRA) | Purchase (P): 507,407 @ $9.35 | EDGAR |
| 2026-04-22 | 4 | First Tracks Biotherapeutics, Inc. (TRAX) | Sale (S): 4,705,575 @ $13.81 | EDGAR |
| 2026-01-12 | 4 | Aktis Oncology, Inc. (AKTS) jointly with NODELMAN OLEG | Conversion (C): 2,270,879 · Conversion (C): 202,862 · Conversion (C): 128,506 · Purchase (P): 2,077,779 @ $18 · Purchase (P): 144,443 @ $18 · Conversion (C): 9,913,810 (derivative) · +6 more | EDGAR |
| 2025-07-30 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 33,931,740 @ $0.11 · Sale (S): 2,687,460 @ $0.10 · Sale (S): 27,433,338 @ $0.10 | EDGAR |
| 2025-06-27 | 4 | Zymeworks Inc. (ZYME) jointly with NODELMAN OLEG | Option exercise/expiry (X): 5,086,480 @ $0.00 · Tax withholding (F): 41 @ $12.71 · Option exercise/expiry (X): 5,086,521 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Zymeworks Inc. (ZYME) jointly with NODELMAN OLEG | Purchase (P): 49,502 @ $11.43 · Purchase (P): 5,919 @ $11.78 | EDGAR |
| 2025-05-16 | 4 | iTeos Therapeutics, Inc. (ITOS) | Purchase (P): 1,658,978 @ $7.41 · Purchase (P): 3,300,000 @ $8 | EDGAR |
| 2025-05-06 | 4 | PROTHENA CORP PUBLIC LTD CO (PRTA) | Sale (S): 3,317,938 @ $8.36 · Sale (S): 977,693 @ $8.11 · Sale (S): 1,984,053 @ $7.64 | EDGAR |
| 2025-04-18 | 4 | Zymeworks Inc. (ZYME) jointly with NODELMAN OLEG | Purchase (P): 73,953 @ $11.16 · Purchase (P): 54,760 @ $11.52 | EDGAR |
| 2025-04-07 | 4 | Zymeworks Inc. (ZYME) jointly with NODELMAN OLEG | Purchase (P): 120,770 @ $11.84 · Purchase (P): 196,438 @ $11.17 | EDGAR |
| 2025-04-02 | 4 | Zymeworks Inc. (ZYME) jointly with NODELMAN OLEG | Purchase (P): 4,397 @ $11.75 · Purchase (P): 48,658 @ $11.60 · Purchase (P): 74,360 @ $11.85 | EDGAR |
| 2025-03-27 | 4 | Zymeworks Inc. (ZYME) jointly with NODELMAN OLEG | Purchase (P): 53,501 @ $12.91 · Purchase (P): 43,848 @ $12.24 | EDGAR |
| 2025-03-24 | 4 | Zymeworks Inc. (ZYME) jointly with NODELMAN OLEG | Purchase (P): 73,476 @ $12.93 · Purchase (P): 31,033 @ $12.78 · Purchase (P): 22,689 @ $13.08 | EDGAR |
| 2025-03-19 | 4 | Zymeworks Inc. (ZYME) jointly with NODELMAN OLEG | Purchase (P): 56,277 @ $12.23 · Purchase (P): 113,880 @ $12.65 · Purchase (P): 58,306 @ $12.64 | EDGAR |
| 2025-03-13 | 4 | Zymeworks Inc. (ZYME) jointly with NODELMAN OLEG | Purchase (P): 320,690 @ $11.49 · Purchase (P): 292,934 @ $12.25 · Purchase (P): 468,356 @ $12.48 | EDGAR |
| 2025-01-21 | 4 | Zymeworks Inc. (ZYME) | Purchase (P): 121,681 @ $13.88 · Purchase (P): 19,748 @ $13.87 | EDGAR |
| 2025-01-15 | 4 | Zymeworks Inc. (ZYME) | Purchase (P): 74,125 @ $13.39 · Purchase (P): 54,500 @ $13.56 · Purchase (P): 39,029 @ $14.01 | EDGAR |
| 2025-01-10 | 4 | Zymeworks Inc. (ZYME) | Purchase (P): 21,021 @ $14.07 · Purchase (P): 204,098 @ $13.13 | EDGAR |
| 2025-01-02 | 4 | ANAPTYSBIO, INC (ANAB) jointly with NODELMAN OLEG | Purchase (P): 65,184 @ $12.92 · Purchase (P): 13,268 @ $12.93 · Purchase (P): 6,646 @ $12.95 | EDGAR |
| 2025-01-02 | 4 | Zymeworks Inc. (ZYME) | Purchase (P): 58,988 @ $14.47 · Purchase (P): 146,501 @ $14.57 · Purchase (P): 157,880 @ $14.78 | EDGAR |
| 2024-12-27 | 4 | Zymeworks Inc. (ZYME) | Purchase (P): 11,958 @ $14.12 · Purchase (P): 16,692 @ $14.38 · Purchase (P): 101,659 @ $14.49 | EDGAR |
| 2024-12-26 | 4/A | Zymeworks Inc. (ZYME) | Purchase (P): 298,818 @ $13.53 · Purchase (P): 704,488 @ $14.08 · Purchase (P): 251,502 @ $14.25 | EDGAR |
| 2024-12-23 | 4 | Mersana Therapeutics, Inc. (MRSN) | Other (J): 8,036,688 · Other (J): 8,036,688 (derivative) | EDGAR |
| 2024-12-23 | 4 | Zymeworks Inc. (ZYME) | Purchase (P): 5,086,521 (derivative) @ $9.83 | EDGAR |
| 2024-11-08 | 4 | Tango Therapeutics, Inc. (TNGX) | Sale (S): 1,494,558 @ $3.28 · Sale (S): 62,318 @ $3.29 · Sale (S): 1,143,124 @ $2.92 | EDGAR |
| 2024-08-16 | 4 | ANAPTYSBIO, INC (ANAB) | Purchase (P): 273,972 @ $36.50 | EDGAR |
| 2023-12-28 | 4 | Zymeworks Inc. (ZYME) | Purchase (P): 5,086,521 (derivative) @ $9.83 | EDGAR |
| 2023-09-22 | 4/A | Nuvation Bio Inc. (NUVB) jointly with NODELMAN OLEG, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, Biotech Opportunity GP, LLC | Purchase (P): 5,143,000 @ $1.26 · Purchase (P): 117,100 @ $1.36 · Purchase (P): 53,000 @ $1.36 | EDGAR |
| 2023-09-21 | 4 | Nuvation Bio Inc. (NUVB) jointly with NODELMAN OLEG, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, Biotech Opportunity GP, LLC | Purchase (P): 5,143,000 @ $1.26 · Purchase (P): 117,100 @ $1.36 · Purchase (P): 53,000 @ $1.36 | EDGAR |
| 2023-06-21 | 4 | Zymeworks Inc. (ZYME) | Purchase (P): 3,350,000 @ $8.12 | EDGAR |
| 2023-05-02 | 4 | Panacea Acquisition Corp. II (PANA) jointly with EcoR1 Panacea Holdings II, LLC, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, Biotech Opportunity GP, LLC, NODELMAN OLEG | Disposition to issuer (D): 545,000 | EDGAR |
| 2023-03-30 | 4 | Zymeworks Inc. (ZYME) | Purchase (P): 200,000 @ $8 | EDGAR |
| 2023-01-23 | 4 | Zymeworks Inc. (ZYME) | Purchase (P): 144,100 @ $9.49 · Purchase (P): 163,400 @ $9.88 | EDGAR |
| 2023-01-18 | 4 | Zymeworks Inc. (ZYME) | Purchase (P): 342,100 @ $9.81 · Purchase (P): 440,000 @ $9.80 · Purchase (P): 203,000 @ $10.00 | EDGAR |
| 2023-01-12 | 4 | Zymeworks Inc. (ZYME) | Purchase (P): 920,000 @ $7.65 · Purchase (P): 106,300 @ $7.87 | EDGAR |
| 2023-01-11 | 4 | Voyager Therapeutics, Inc. (VYGR) | Sale (S): 456,000 @ $7.67 · Sale (S): 336,400 @ $8.05 · Sale (S): 110,000 @ $8.50 | EDGAR |
| 2022-06-23 | 4 | Voyager Therapeutics, Inc. (VYGR) | Purchase (P): 101,400 @ $5.28 · Purchase (P): 376,000 @ $5.66 | EDGAR |
| 2022-05-09 | 4 | ANAPTYSBIO, INC (ANAB) jointly with NODELMAN OLEG | Purchase (P): 668,237 @ $21.63 · Sale (S): 668,237 @ $21.63 | EDGAR |
| 2022-05-09 | 4 | PROTHENA CORP PUBLIC LTD CO (PRTA) | Purchase (P): 1,062,736 @ $29.02 · Sale (S): 1,062,736 @ $29.02 | EDGAR |
| 2022-01-12 | 4 | PROTHENA CORP PUBLIC LTD CO (PRTA) | Purchase (P): 300,000 @ $37.50 | EDGAR |
| 2021-12-10 | 4 | Odonate Therapeutics, Inc. (ODT) | Purchase (P): 185,941 @ $1.66 · Sale (S): 185,941 @ $1.66 · Sale (S): 156,669 @ $1.82 · Sale (S): 5,000,000 @ $1.66 · Sale (S): 545,000 @ $1.55 | EDGAR |
| 2021-11-30 | 4 | Nuvation Bio Inc. (NUVB) jointly with NODELMAN OLEG, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, Biotech Opportunity GP, LLC | Purchase (P): 151,544 @ $10.45 · Sale (S): 151,544 @ $10.45 · Purchase (P): 56,598 @ $8.64 · Sale (S): 56,598 @ $8.64 · Purchase (P): 163,268 @ $7.69 · Purchase (P): 21,758 @ $7.69 | EDGAR |
| 2021-10-01 | 4 | Corvus Pharmaceuticals, Inc. (CRVS) | Sale (S): 3,000,000 @ $5.04 · Sale (S): 2,000,000 @ $4.96 | EDGAR |
| 2021-06-22 | 4 | PROTHENA CORP PUBLIC LTD CO (PRTA) | Option exercise/expiry (X): 250,000 @ $30 · Option exercise/expiry (X): 2,500 (derivative) @ $0 | EDGAR |
| 2021-05-04 | 4 | ANAPTYSBIO, INC (ANAB) jointly with NODELMAN OLEG | Purchase (P): 35,700 @ $23.16 · Purchase (P): 20,800 @ $23.31 · Purchase (P): 165,000 @ $23.25 | EDGAR |
| 2021-04-27 | 4 | ANAPTYSBIO, INC (ANAB) jointly with NODELMAN OLEG | Purchase (P): 99,600 @ $23.54 · Purchase (P): 13,900 @ $23.80 · Purchase (P): 33,800 @ $23.82 | EDGAR |
| 2021-04-13 | 4 | Panacea Acquisition Corp. II (PANA) jointly with EcoR1 Panacea Holdings II, LLC, NODELMAN OLEG, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, Biotech Opportunity GP, LLC | Purchase (P): 545,000 @ $10 | EDGAR |
| 2021-04-13 | 4 | Nuvation Bio Inc. (NUVB) jointly with NODELMAN OLEG, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, EcoR1 Panacea Holdings, LLC, Biotech Opportunity GP, LLC | Purchase (P): 262,230 @ $10.03 · Purchase (P): 37,770 @ $10.03 · Purchase (P): 116,255 @ $9.49 · Purchase (P): 16,745 @ $9.49 · Purchase (P): 27,534 @ $10.27 · Purchase (P): 3,966 @ $10.27 | EDGAR |
| 2021-03-25 | 4 | PROTHENA CORP PUBLIC LTD CO (PRTA) | Purchase (P): 875,000 @ $20.75 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-03 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1587114 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs